Wow, this is a big moment for the stem cell community. We officially crossed 300,000 stem cell publications released to PubMed.gov. PubMed is a service of the U.S. National Library of Medicine and NIH that comprises more than 27 million citations for biomedical literature.[1] It is the largest and comprehensive global database that exists for scientific publications. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
Donor Egg Bank to Provide Free Cord Blood Processing through FamilyCord
World’s Largest Frozen Egg Bank offers a Lifetime of Security
Rockville, MD, Aug. 1, 2017— Donor Egg Bank, a California Cryobank company, continues to set the standard for the frozen donor egg industry by offering a truly once in lifetime opportunity to their intended parents – free processing for their future babies’ cord blood stem cells through sister company FamilyCord – a $1,500 savings.
AgeX Therapeutics Obtains $10 Million in Capital and Commences Operations
August 02, 2017, ALAMEDA, Calif.–AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE MKT: BTX), today reported that it has successfully raised $10 million in equity financing to fund its operations. Following the financing, BioTime continues to own about 87% of AgeX’s outstanding shares. The financing is expected to fund preclinical development at AgeX as well as building the company’s operational infrastructure. The financing may also lead to a registration and distribution of a to-be-determined percentag of the AgeX shares to BioTime shareholders, after which AgeX would trade as a public company. [Read more…]
Capricor Announces Results of FDA Meeting on Intravenous CAP-1002 for Duchenne Muscular Dystrophy
LOS ANGELES, July 27, 2017 — Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy (DMD) and other rare diseases, today announced that it has received official minutes of the meeting held recently between the U.S. Food and Drug Administration (FDA) and Capricor to discuss the development of intravenous CAP-1002 (allogeneic cardiosphere-derived cells) for the treatment of Duchenne muscular dystrophy (DMD).
Cesca Therapeutics Acquires Cell Processing Systems of SynGen
RANCHO CORDOVA, Calif., July 10, 2017 –Â Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that its wholly-owned subsidiary, ThermoGenesis Corp., has entered into an asset acquisition agreement (the “Agreement”) with SynGen Inc., a privately-held Sacramento, CA-based technology company active in the cellular processing field.
[Read more…]
- « Previous Page
- 1
- …
- 133
- 134
- 135
- 136
- 137
- …
- 145
- Next Page »